Somewhat Positive Press Coverage Somewhat Unlikely to Affect Exelixis (EXEL) Stock Price

News headlines about Exelixis (NASDAQ:EXEL) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Exelixis earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.1912463458258 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

A number of research firms have issued reports on EXEL. William Blair reissued a “buy” rating on shares of Exelixis in a research note on Wednesday, April 11th. BidaskClub lowered shares of Exelixis from a “sell” rating to a “strong sell” rating in a research note on Wednesday, April 4th. Cann reaffirmed a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research note on Tuesday, March 20th. Zacks Investment Research raised shares of Exelixis from a “sell” rating to a “hold” rating in a research note on Monday, March 19th. Finally, TheStreet lowered shares of Exelixis from a “b” rating to a “c+” rating in a research note on Thursday, March 15th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company. Exelixis presently has a consensus rating of “Hold” and a consensus target price of $34.10.

Shares of NASDAQ:EXEL traded down $0.22 during trading on Friday, reaching $20.87. The company had a trading volume of 2,337,390 shares, compared to its average volume of 3,581,289. The firm has a market cap of $6,256.54, a P/E ratio of 40.92 and a beta of 2.10. Exelixis has a twelve month low of $18.03 and a twelve month high of $32.50.

Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, February 26th. The biotechnology company reported $0.12 EPS for the quarter, hitting analysts’ consensus estimates of $0.12. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. The business had revenue of $120.10 million for the quarter, compared to the consensus estimate of $120.25 million. During the same period in the previous year, the firm earned $0.12 EPS. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. equities analysts forecast that Exelixis will post 0.58 earnings per share for the current fiscal year.

In related news, Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $20.25, for a total value of $303,750.00. Following the sale, the director now directly owns 76,329 shares in the company, valued at approximately $1,545,662.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Morrissey sold 90,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 11th. The stock was sold at an average price of $20.78, for a total transaction of $1,870,200.00. The disclosure for this sale can be found here. Insiders sold a total of 210,029 shares of company stock worth $4,877,737 over the last quarter. Insiders own 5.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with's FREE daily email newsletter.

Leave a Reply